Clinical trials: PARP Inhibitor
Ovarian Cancer, Fallopian Tube Cancer
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
This study evaluates whether the adoption of the RADAR dosing strategy could further reduce treatment related toxicities improving the safety profile of niraparib.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- Newton (NCT03891576)
- Testing
- Niraparib
- Where
- 12 sites in Germany, Italy
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Human Volunteers
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
This is a randomized, 2-period, 2-sequence crossover study to evaluate the effect of food on the relative bioavailability of BMN 673 during fasting and fed conditions in healthy male subjects.
- Trial name
- NCT01776437
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Solid Tumor, Ovarian Cancer
Effect of PARP Inhibitors on Glomerular Filtration Rate
The purpose of this study is to observe whether PARP inhibitors have an effect on serum creatinine level, and whether this reflects a change in creatinine secretion or a true change in kidney function.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04367467
- Testing
- Kidney Function Test
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania